Skip Navigation

European Heart Journal 2004 25(4):335-341; doi:10.1016/j.ehj.2003.12.004
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hoppmann, P.
Right arrow Articles by Kastrati, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoppmann, P.
Right arrow Articles by Kastrati, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Clinical research

The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions

Petra Hoppmann, Werner Koch*, Albert Schömig and Adnan Kastrati

Deutsches Herzzentrum München and 1. Medizinische Klinik rechts der Isar, Technische Universität München, München, Germany

* Correspondence to: Werner Koch, PhD, Deutsches Herzzentrum München, Lazarettstrasse 36, 80636 München, Germany. Tel: +49-89-1218-2601; Fax: +49-89-1218-3053
E-mail address: wkoch{at}dhm.mhn.de

Received 13 May 2003; revised 21 November 2003; accepted 4 December 2003

Abstract

Aims Matrix metalloproteinase stromelysin-1 has been implicated in the process of exaggerated lumen re-narrowing after primarily successful interventions in coronary arteries. We examined the possibility that the 5A/6A promoter polymorphism of the stromelysin-1 gene is associated with restenosis after stenting or percutaneous transluminal coronary angioplasty (PTCA).

Methods and results The study included 3333 consecutive patients with symptomatic coronary artery disease who were treated with stent implantation (n=2857) or PTCA (n=476). Primary end-point was angiographic restenosis, defined as ≥50% diameter stenosis at 6-month follow-up angiography. Restenosis rates were 28.1%, 27.8%, and 29.5% in carriers of the stromelysin-1 genotypes 5A5A, 5A6A, and 6A6A, respectively (P=0.71). The incidence of death or myocardial infarction and the need for revascularization at the site of the intervention due to symptoms or signs of ischaemia in the presence of angiographic restenosis were not significantly different between the genotype groups at 1 year. Separate analysis of the patients who underwent stenting and the patients who were treated with PTCA did not indicate the existence of a treatment type-related association between the 5A/6A polymorphism and restenosis.

Conclusion Our data strongly suggest that the 5A/6A polymorphism of the stromelysin-1 gene is not related to angiographic restenosis or the 1-year clinical outcome after interventions in coronary arteries.

Key Words: Stromelysin-1 • Stents • PTCA • Restenosis • Genetics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Med. Genet.Home page
S. Abilleira, S. Bevan, and H. S Markus
The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis
J. Med. Genet., December 1, 2006; 43(12): 897 - 901.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
C. J. Glueck, M. Haque, M. Winarska, S. Dharashivkar, R. N. Fontaine, B. Zhu, and P. Wang
Stromelysin-1 5A/6A and eNOS T-786C Polymorphisms, MTHFR C677T and A1298C Mutations, and Cigarette-Cannabis Smoking: A Pilot, Hypothesis-Generating Study of Gene-Environment Pathophysiological Associations With Buerger's Disease
Clinical and Applied Thrombosis/Hemostasis, October 1, 2006; 12(4): 427 - 439.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
S. Ye
Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome
Cardiovasc Res, February 15, 2006; 69(3): 636 - 645.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. Koch, W. Latz, M. Eichinger, C. Ganser, A. Schomig, and A. Kastrati
Genotyping of the Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism by the TaqMan Method
Clin. Chem., August 1, 2005; 51(8): 1547 - 1549.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.